A first-time-in-human single ascending dose trial of TRV250 for the treatment of acute migraine
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2018
At a glance
- Drugs TRV 250 (Primary) ; TRV 250 (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man; Pharmacokinetics
- 28 Jun 2018 Status changed from active, no longer recruiting to completed, according to a Trevena media release.
- 07 Mar 2018 According to a Trevena media release, dosing in this study has been completed and reached a top subcutaneous dose of 30 mg. Company expects to release data in the coming months.
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting, According to a Trevena media release.